Structure Therapeutics Appoints Angus C. Russell to Board of Directors
August 27, 2024 16:05 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
August 26, 2024 16:05 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
August 08, 2024 16:05 ET
|
Structure Therapeutics Inc.
GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter...
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
June 07, 2024 16:05 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
June 05, 2024 19:53 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
June 03, 2024 16:09 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
June 03, 2024 07:30 ET
|
Structure Therapeutics Inc.
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the...
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
May 09, 2024 16:05 ET
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human...
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
March 08, 2024 16:05 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
March 08, 2024 08:30 ET
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in...